Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the CAGR of the Sickle Cell Disease Treatment Market Influence Its Overall Growth by 2034?

There has been a swift expansion in the market size for treating sickle cell diseases in the past few years. The market size is projected to rise from $2.95 billion in 2024 to $3.54 billion in 2025, with a compound annual growth rate (CAGR) of 19.7%. Factors contributing to the substantial growth during the historic period include increased knowledge about the disease, the use of blood transfusions, pain management strategies, and hydroxyurea therapy.

The market size for treatment of sickle cell disease is predicted to experience a speedy expansion in the forthcoming years, reaching $6.8 billion in 2029, with a compound annual growth rate (CAGR) of 17.7%. This upsurge during the projection period can be credited to elements like gene editing and therapy, the development of new medications, utilization of telemedicine and remote monitoring, along with worldwide health initiatives. Key trends predicted for this timeframe encompass curing therapies, alternative methods for pain management, international collaborations, and increased focus on patient advocacy and engagement.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Sickle Cell Disease Treatment Market?

The expected surge in blood transfusion requirements is poised to spur the expansion of the market for sickle cell disease treatments. Blood transfusion, a medical practice involving the transfer of blood or blood products from a donor to a recipient, plays an integral role in managing sickle cell disease. This procedure aids in enhancing the oxygen-carrying ability of blood and alleviates complications tied to vaso-occlusion. As reported by the Mid-Atlantic Long-Term Care, a company in the USA that offers specialist 24-hour triage on-call assistance, around 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma are required daily in the USA as of January 2022. As a result, the growing need for blood transfusion is stimulating the sickle cell disease treatment market’s growth. For the Sickle Cell Disease Treatment Market, a key driving factor is the rise in blood and bone marrow transplantation, leading to advancements in treatments for this disease. The process entails the substitution of unwell blood-forming cells with healthy ones, making it highly beneficial in curing sickle cell diseases and cancers. The goal of a bone marrow transplant is to supplant unhealthy bone marrow, which has been treated to discard the defective cells, with healthy marrow cells. These replacement cells can be either autologous (from the patient’s body) or allogenic (from a donor’s body). The National Transplant Organization (ONT) in Spain reported in June 2024 that Spain registered an 8% increase in its Bone Marrow Donor Registry, reaching a total of 23,686 donors in 2023, and performed a record 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million population. This rising trend in blood and bone marrow transplants is projected to invigorate the sickle cell disease treatment market.

Request Your Free Sickle Cell Disease Treatment Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp

Who Are the Leading Companies Pioneering Change in the Sickle Cell Disease Treatment Market?

Major companies operating in the sickle cell disease treatment market are:

• Sun Pharmaceutical Industries Ltd._x000D_

• Pfizer Inc._x000D_

• Johnson & Johnson Private Limited_x000D_

• Merck & Co Inc._x000D_

• Novartis AG_x000D_

What Are the Most Significant Trends Transforming the Sickle Cell Disease Treatment Market Today?

Leading firms in the market for sickle cell disease treatments are striving to create new oral suspension medicines to enhance patient compliance, augment the effectiveness of the drug, and offer easier treatment methods, particularly for pediatric and elderly patients. Oral suspension drugs are medications in liquid form that contain solid particles, designed to simplify the swallowing process, especially for children or individuals having difficulty with pill ingestion. For example, in March 2024, a company originating from India, Akums Drugs and Pharmaceuticals Ltd., specializing in pharmaceutical preparation manufacturing, introduced a Hydroxyurea oral suspension that remains stable at room temperature. This affordable, room-temperature-stable sickle cell disease treatment aims to boost accessibility in India. With a cost less than 1% of imported equivalents, it provides exact dosage administration via oral syringes, which benefits patients of all ages without the necessity for cold storage.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report

What Major Market Segments Define the Scope and Growth of the Sickle Cell Disease Treatment Market?

The sickle cell disease treatment market covered in this report is segmented –

1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant

2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types

3) By Route Of Administration: Oral, Parenteral

4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion

2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab

3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant

Which Regions Are Leading the Charge in Sickle Cell Disease Treatment Market Development?

North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Scope and Reach of the Sickle Cell Disease Treatment Market Defined?

Sickle cell disease (SCD), also known as sickle cell anemia, is a genetic disorder affecting hemoglobin, a protein in red blood cells. A mutation in the hemoglobin gene causes the production of defective hemoglobin, referred to as hemoglobin S (HbS), in people with sickle cell disease. The sickle cell disease treatment removes blockages, enhances blood flow and repairs damaged tissues.

Browse Through More Similar Reports By The Business Research Company:

Blood And Blood Components Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

Blood Culture Tests Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-culture-tests-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: